CClinicalTrials.gg
RecruitingNCT06229275Updated Jul 20, 2025

Comparing Effectiveness of Physician-assisted Versus Self-assisted Pap Smear Collection

An interventional study of Pap smear collection using the Personal Pap Smear (PPS) Device and Active Comparator: Pap smear collection using the Rovers Cervex-Brush in Cervical Cancer Screening, sponsored by Morehouse School of Medicine. Recruiting at 1 site in United States. Open to female participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Morehouse School of Medicine · Not applicable, Interventional, and Screening

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
Female
01

Study summary

This purpose of this research study is to determine the effectiveness of the Personal Pap Smear Device™ to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).

Read the detailed description

To determine the effectiveness of the Personal Pap Smear Device™ to collect adequate (as defined by Bethesda Guidelines 2014) cervical cell samples for cytology examination as compared with the Rover Cervex-Brush (Cervix-Examination Brush).

02

Conditions studied

  • Cervical Cancer Screening

Keywords

  • pap smear collection
03

In context

Lead sponsor

Morehouse School of Medicine is the lead sponsor of 22 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult women, aged 21-65 years old.
  • Do not have any medical or psychiatric condition affecting the ability to give voluntary informed consent.
  • Be able to read and understand English

Exclusion criteria

Exclusion Criteria:

  • Participants currently on menses
  • Inability to provide Informed Consent
  • Previous total hysterectomy
  • History of radiation treatment for cervical cancer
  • Pregnancy
  • Medical condition that interferes with conduct of study, in investigator's opinion
  • Evidence of active cervical infection requiring treatment
  • Known bleeding diathesis
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Pap smear collection using the Personal Pap Smear (PPS) Device

    The investigational device, trade named the Personal Pap Smear™ (PPS) developed by GyneConcepts of Atlanta, Georgia. It arrives completely assembled, and ready-for-use, in a sealed plastic bag. The PPS device is a multi-component assembly designed for the collection of exfoliated cervical epithelial cells. Its four major components are the (1) Tube Body, (2) U-Ring and attached Aligning Spoon, (3) Ball Handle, (with permanently anchored bristle Collection Brush), and (4) Safety Cover.

    Device: Pap smear collection using the Personal Pap Smear (PPS) Device

  • Active comparator
    Pap smear collection using the Rovers Cervex-Brush

    The Predicate device utilized in this study is the Cervix-Examination Brush, manufactured by Rover (Manufacturers Code: 9443). The Cervex-Brush (CervixExamination Brush) is made of polyethylene and has a total length of 20 centimeters. The top portion uses a soft flexible brush to obtain cell samples. The brush consists of 57 semi-circular plastic bristles of various lengths. The shape is such that the top edges of the brush follow the contours of the cervix. The longer middle bristles reach deep into the endocervical canal- 'Os'. The shorter bristles touch both the ectocervical area and transformation zone at the same time. This device is packaged with identical standards used for packaging commercial tampons.

    Device: Active Comparator: Pap smear collection using the Rovers Cervex-Brush

Interventions

  • DevicePap smear collection using the Personal Pap Smear (PPS) Device

    Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.

  • DeviceActive Comparator: Pap smear collection using the Rovers Cervex-Brush

    Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.

06

What researchers measure

Primary outcomes

  1. Comparison of the samples for the Predicate Device versus PPS device

    Data of Adequate versus Inadequate will be reported to include a positive percent agreement (PPA) defined as PPA= A/(A+C) and the negative percent agreement (NPA) defined as NPA = D/(B+D) along with their 95% confidence bounds using the Clopper-Pearson method.

    Time frame: Baseline

Secondary outcomes

  1. The Comparison of Cell Types of the PPS Device versus the Predicate Device

    The PPS Device and the Predicate Device cell types will be measured against the 2014 Bethesda cytology categories that will be displayed in a 8 x 8 contingency table.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Morehouse School of Medicine
    Atlanta, Georgia 30310, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06229275
Lead sponsor
Morehouse School of Medicine
Collaborators
GyneConcepts, Inc.
Responsible party
Regina Leonis (Assistant Professor, Morehouse School of Medicine) — Principal investigator
First posted
Jan 29, 2024
Start date
Jul 25, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Jul 20, 2025

Study contacts

Regina K Leonis, MD
Contact
rleonis@msm.edu
4047565713
LaShawn Mays, MSM
Contact
lmays@msm.edu
4047521971
Regina K Leonis, MD, MD
principal investigator · Morehouse School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion